Selective increase in the sensitivity of tumours to chemotherapy with n-3 polyunsaturated fatty acids
Since long chain polyunsaturated fatty acids (PUFA) are good substrate for peroxidation, a biochemical correlate of cancer cell programmed death and since some cytotoxic agents such as anthracyclins are known to induce oxidative stress, we looked for the effect of PUFA on the response of the cancer...
Gespeichert in:
Veröffentlicht in: | Oléagineux corps gras lipides 2000-01, Vol.7 (1) |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | fre |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Since long chain polyunsaturated fatty acids (PUFA) are good substrate for peroxidation, a biochemical correlate of cancer cell programmed death and since some cytotoxic agents such as anthracyclins are known to induce oxidative stress, we looked for the effect of PUFA on the response of the cancer disease to anthracyclins-based chemotherapy. Breast cancer patients with elevated DHA content in white adipose tissues taken as an indicator of post dietary intake had a better response rate to anthracyclines-containing neoadjuvant chemotherapy than patients with low DHA level, suggesting that chemosensitivity of the carcinoma was higher when DHA availability to the tumor tissue was greater. Such a hypothesis was examined using human breast carcinoma cell cultures. Long chain PUFA and especially docosahexaenoic acid (22:6n-3) increased the sensitivity of breast cancer cell lines to anthracyclins. Using the rat model of NMU-induced mammary tumors, an increased efficacy of anthracyclins on mammary tumors without change in cardiac toxicity in the dietary group supplemented with fish oil, enriched in n-3PUFAs or with purified DHA was documented. This shows that this fatty acid also sensitizes the tumor in vivo. A clinical trial investigating the potential of dietary DHA to increase the response rate of measurable metastatic tumors in breast cancer patients will be conducted shortly |
---|---|
ISSN: | 1258-8210 2257-6614 |
DOI: | 10.1051/ocl.2000.0060 |